| Literature DB >> 35008181 |
Chung-Jan Kang1, Yu-Wen Wen2,3, Shu-Ru Lee4, Li-Yu Lee5, Chuen Hsueh5, Chien-Yu Lin6, Kang-Hsing Fan6, Hung-Ming Wang7, Chia-Hsun Hsieh7, Shu-Hang Ng8, Chih-Hua Yeh8, Chih-Hung Lin9, Chung-Kan Tsao9, Tuan-Jen Fang1, Shiang-Fu Huang1, Li-Ang Lee1, Ku-Hao Fang1, Tzu-Chen Yen10, Nai-Ming Cheng10, Tsung-You Tsai1, Shiao-Fwu Tai1, Chi-Ying Tsai11.
Abstract
(1) Background: The optimal cutoff value that maximizes the prognostic value of surgical margins in patients with resected oral cavity squamous cell carcinoma has not yet been identified. (2)Entities:
Keywords: local control; nationwide registry study; oral cavity squamous cell carcinoma; outcome; surgical margin
Year: 2021 PMID: 35008181 PMCID: PMC8749941 DOI: 10.3390/cancers14010015
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1Flow of patients through the study. OCSCC, oral squamous cell carcinoma.
General characteristics of patients with oral cavity squamous cell carcinoma stratified according to different margin statuses (0, 0.1–4 and > 4 mm).
| Characteristic | Margin Status 0 mm ( | Margin Status 0.1–4 mm ( | Margin Status >4 mm ( |
|
|---|---|---|---|---|
| Sex (No., %) | ||||
| Male (12,548, 91.1) | 760 (92.1) | 5548 (90.9) | 6240 (91.3) | 0.4447 |
| Female (1220, 8.9) | 65 (7.9) | 557 (9.1) | 598 (8.7) | |
| Age, years (No., %) | ||||
| <65 (11,733, 85.2) | 695 (84.2) | 5194 (85.1) | 5844 (85.5) | 0.5927 |
| ≥65 (2035, 14.8) | 130 (15.8) | 911 (14.9) | 994 (14.5) | |
| Pathologic T status (No., %) | ||||
| T1 (2799, 20.3) | 62 (7.5) | 1270 (20.8) | 1467 (21.5) | <0.0001 |
| T2 (4454, 32.4) | 159 (19.3) | 2008 (32.9) | 2287 (33.4) | |
| T3 (2094, 15.2) | 137 (16.6) | 956 (15.7) | 1001 (14.6) | |
| T4 (4421, 32.1) | 467 (56.6) | 1871 (30.6) | 2083 (30.5) | |
| Pathologic N status (No., %) | ||||
| pN0 (9227, 67.0) | 385 (46.7) | 3996 (65.5) | 4846 (70.9) | <0.0001 |
| pN1 (1303, 9.5) | 98 (11.9) | 618 (10.1) | 587 (8.6) | |
| pN2 (1487, 10.8) | 124 (15.0) | 697 (11.4) | 666 (9.7) | |
| pN3 (1751, 12.7) | 218 (26.4) | 794 (13.0) | 739 (10.8) | |
| Pathologic stage (No., %) | ||||
| I (2449, 17.8) | 49 (5.9) | 1098 (18.0) | 1302 (19.0) | <0.0001 |
| II (3198, 23.2) | 86 (10.4) | 1389 (22.8) | 1723 (25.2) | |
| III (2108, 15.3) | 109 (13.2) | 996 (16.3) | 1003 (14.7) | |
| IV (6013, 43.7) | 581 (70.5) | 2622 (42.9) | 2810 (41.1) | |
| Depth of invasion, (No., %), mm | ||||
| <10 (7322, 53.2) | 277 (33.6) | 3312 (54.3) | 3733 (54.6) | <0.0001 |
| ≥10 (6446, 46.8) | 548 (66.4) | 2793 (45.7) | 3105 (45.4) | |
| Extra-nodal extension (No., %) | ||||
| No (11,620, 84.4) | 573 (69.5) | 5133 (84.1) | 5914 (86.5) | <0.0001 |
| Yes (2148, 15.6) | 252 (30.5) | 972 (15.9) | 924 (13.5) | |
| Treatment modality (No., %) | ||||
| S alone (6749, 49.0) | 165 (20.0) | 2861 (46.9) | 3723 (54.4) | <0.0001 |
| S plus CT+S plus RT+S plus CT and RT (7019, 51.0) | 660 (80.0) | 3244 (53.1) | 3115 (45.6) | |
| Second primary tumors (No., %) | ||||
| No (12,176, 88.4) | 734 (89.0) | 5400 (88.5) | 6042 (88.4) | 0.8734 |
| Yes (1592, 11.6) | 91 (11.0) | 705 (11.5) | 796 (11.6) | |
| Site (No., %) | ||||
| Lip (596, 4.3) | 20 (2.4) | 223 (3.7) | 353 (5.2) | <0.0001 |
| Tongue (5252, 38.1) | 198 (24.0) | 2196 (36.0) | 2858 (41.8) | |
| Gum (1803, 13.1) | 174 (21.1) | 792 (13.0) | 837 (12.2) | |
| Mouth floor (511, 3.7) | 45 (5.5) | 260 (4.3) | 206 (3.0) | |
| Palate (181, 1.3) | 34 (4.1) | 73 (1.2) | 74 (1.1) | |
| Buccal (4463, 32.4) | 267 (32.4) | 2167 (35.5) | 2029 (29.7) | |
| Retromolar (606, 4.4) | 56 (6.8) | 252 (4.1) | 298 (4.4) | |
| Other sites (356, 2.7) | 31 (3.7) | 142 (2.2) | 183 (2.6) | |
| Tumor differentiation (No., %) | ||||
| Well differentiated (3786, 27.5) | 198 (24.0) | 1648 (27.0) | 1940 (28.4) | <0.0001 |
| Moderately differentiated (8674, 63.0) | 509 (61.7) | 3877 (63.5) | 4288 (62.7) | |
| Poorly differentiated (1308, 9.5) | 118 (14.3) | 580 (9.5) | 610 (8.9) |
Other sites: tumors arising from the retromolar trigone or overlapping regions. Abbreviations: S, surgery; CT, chemotherapy; RT, radiotherapy.
Figure 2(A) Five-year local control rates of patients with oral cavity squamous cell carcinoma stratified according to different margin statuses (0, 0.1–4 and > 4 mm); (B) five-year disease-specific survival rates of patients with oral cavity squamous cell carcinoma stratified according to different margin statuses (0, 0.1–4 and > 4 mm); (C) five-year overall survival rates of patients with oral cavity squamous cell carcinoma stratified according to different margin statuses (0, 0.1–4 and > 4 mm).
Univariate and multivariate analyses of different outcome measures.
| Risk Factor | Five-Year Local Control | Five-Year Disease-Specific Survival | Five-Year Overall Survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis-Stepwise | Univariate Analysis | Multivariate Analysis-Stepwise | Univariate Analysis | Multivariate Analysis-Stepwise | |||||||
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| |
| Margin status | ||||||||||||
| >4 mm | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| 0.1–4 mm | 1.46 (1.29–1.64) | <0.0001 | 1.42 (1.26–1.61) | <0.0001 | 1.32 (1.22–1.42) | <0.0001 | 1.24 (1.15–1.33) | <0.0001 | 1.28 (1.20–1.36) | <0.0001 | 1.23 (1.15–1.31) | <0.0001 |
| 0 mm | 1.79 (1.44–2.23) | <0.0001 | 1.56 (1.25–1.95) | <0.0001 | 2.74 (2.43–3.08) | <0.0001 | 1.70 (1.51–1.92) | <0.0001 | 2.52 (2.27–2.79) | <0.0001 | 1.69 (1.52–1.88) | <0.0001 |
| Sex | ||||||||||||
| Female | 1 | − | − | 1 | 1 | 1 | 1 | |||||
| Male | 1.19 (0.95–1.47) | 0.1263 | − | − | 1.05 (0.92–1.19) | 0.4754 | 1.15 (1.01–1.33) | 0.0349 | 1.10 (0.99–1.23) | 0.0858 | 1.21 (1.08–1.36) | 0.0008 |
| Age, years | ||||||||||||
| <65 | 1 | − | − | 1 | 1 | 1 | 1 | |||||
| ≥65 | 0.91 (0.77–1.08) | 0.2677 | − | − | 1.25 (1.14–1.38) | <0.0001 | 1.30 (1.18–1.43) | <0.0001 | 1.50 (1.39–1.62) | <0.0001 | 1.62 (1.50–1.75) | <0.0001 |
| Pathologic T status | ||||||||||||
| T1-2 | 1 | − | − | 1 | 1 | 1 | 1 | |||||
| T3-4 | 1.25 (1.11–1.40) | 0.0001 | − | − | 2.77 (2.57–2.99) | <0.0001 | 1.38 (1.22–1.57) | <0.0001 | 2.47 (2.32–2.63) | <0.0001 | 1.49 (1.36–1.64) | <0.0001 |
| Pathologic N status | ||||||||||||
| pN0 | 1 | − | − | 1 | 1 | 1 | 1 | |||||
| pN1-3 | 1.32 (1.17–1.48) | <0.0001 | − | − | 4.14 (3.86–4.45) | <0.0001 | 2.14 (1.92–2.39) | <0.0001 | 3.44 (3.24–3.65) | <0.0001 | 2.05 (1.90–2.22) | <0.0001 |
| Pathologic stage | ||||||||||||
| I-II | 1 | − | − | 1 | 1 | 1 | − | − | ||||
| III-IV | 1.34 (1.19–1.51) | <0.0001 | − | − | 4.31 (3.92–4.74) | <0.0001 | 1.32 (1.13–1.54) | 0.0004 | 3.37 (3.13–3.63) | <0.0001 | − | − |
| Depth of invasion | ||||||||||||
| <10 mm | 1 | − | − | 1 | 1 | 1 | 1 | |||||
| ≥10 mm | 1.29 (1.15–1.45) | <0.0001 | 1.22 (1.09–1.38) | 0.0010 | 2.60 (2.42–2.81) | <0.0001 | 1.31 (1.18–1.46) | <0.0001 | 2.33 (2.19–2.48) | <0.0001 | 1.31 (1.19–1.43) | <0.0001 |
| Extra-nodal extension | ||||||||||||
| No | 1 | − | − | 1 | 1 | 1 | 1 | |||||
| Yes | 1.39 (1.20–1.60) | <0.0001 | − | − | 4.35 (4.04–4.68) | <0.0001 | 1.82 (1.66–1.99) | <0.0001 | 3.89 (3.65–4.15) | <0.0001 | 1.78 (1.64–1.93) | <0.0001 |
| Treatment modality | ||||||||||||
| S alone | 1 | − | − | 1 | − | − | 1 | − | − | |||
| S plus CT + S plus RT + S plus both CT and RT | 1.25 (1.11–1.40) | 0.0002 | − | − | 2.74 (2.53–2.96) | <0.0001 | − | − | 2.30 (2.16–2.45) | <0.0001 | − | − |
| Second primary | ||||||||||||
| No | 1 | − | − | 1 | − | − | 1 | 1 | ||||
| Yes | 0.93 (0.78–1.12) | 0.4456 | − | − | 1.02 (0.92–1.13) | 0.7575 | − | − | 1.76 (1.63–1.90) | <0.0001 | 1.71 (1.58–1.84) | <0.0001 |
| Site | ||||||||||||
| Lip | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Tongue | 1.24 (0.88–1.77) | 0.2238 | 1.15 (0.81–1.63) | 0.4516 | 1.32 (1.09–1.62) | 0.0056 | 1.01 (0.82–1.23) | 0.9627 | 1.14 (0.98–1.34) | 0.0995 | 0.92 (0.78–1.08) | 0.3140 |
| Gum | 1.45 (0.99–2.10) | 0.0538 | 1.30 (0.90–1.89) | 0.1677 | 1.63 (1.32–2.02) | <0.0001 | 1.14 (0.92–1.41) | 0.2312 | 1.35 (1.14–1.60) | 0.0005 | 0.99 (0.83–1.17) | 0.8679 |
| Mouth floor | 0.83 (0.49–1.40) | 0.4781 | 0.72 (0.42–1.21) | 0.2129 | 1.24 (0.95–1.62) | 0.1191 | 0.81 (0.62–1.06) | 0.1252 | 1.34 (1.08–1.65) | 0.0069 | 0.91 (0.73–1.12) | 0.3677 |
| Palate | 2.17 (1.26–3.73) | 0.0053 | 1.95 (1.13–3.36) | 0.0167 | 1.99 (1.45–2.75) | <0.0001 | 1.42 (1.03–1.96) | 0.0322 | 1.90 (1.46–2.47) | <0.0001 | 1.42 (1.09–1.85) | 0.0090 |
| Buccal | 1.86 (1.32–2.64) | 0.0005 | 1.73 (1.22–2.45) | 0.0021 | 1.22 (1.00–1.50) | 0.0483 | 0.98 (0.80–1.20) | 0.8757 | 1.06 (0.90–1.24) | 0.5191 | 0.91 (0.77–1.07) | 0.2509 |
| Retromolar | 2.29 (1.53–3.43) | <0.0001 | 2.10 (1.40–3.15) | 0.0003 | 1.49 (1.16–1.91) | 0.0016 | 1.13 (0.88–1.45) | 0.3272 | 1.24 (1.01–1.52) | 0.0400 | 1.01 (0.82–1.24) | 0.9566 |
| Other sites | 2.05 (1.30–3.23) | 0.0019 | 1.87 (1.19–2.95) | 0.0069 | 1.51 (1.14–2.00) | 0.0039 | 1.08 (0.81–1.43) | 0.6074 | 1.40 (1.12–1.77) | 0.0038 | 1.08 (0.86–1.36) | 0.5189 |
| Tumor differentiation | ||||||||||||
| Well differentiated | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Moderately differentiated | 1.22 (1.07–1.40) | 0.0036 | 1.20 (1.05–1.38) | 0.0089 | 1.62 (1.48–1.77) | <0.0001 | 1.24 (1.13–1.36) | <0.0001 | 1.51 (1.40–1.63) | <0.0001 | 1.22 (1.13–1.32) | <0.0001 |
| Poorly differentiated | 1.28 (1.03–1.59) | 0.0231 | 1.19 (0.95–1.48) | 0.1277 | 3.03 (2.69–3.41) | <0.0001 | 1.66 (1.47–1.88) | <0.0001 | 2.86 (2.59–3.17) | <0.0001 | 1.73 (1.56–1.92) | <0.0001 |
Other sites: tumors arising from the retromolar trigone or overlapping regions. Abbreviations: HR, hazard ratio; CI, confidence interval; S, surgery; CT, chemotherapy; RT, radiotherapy.
Summary of published studies on the prognostic impact of surgical resection margins and associated clinical outcomes in oral malignancies.
| Authors (Recruitment Year) | Patients (n) | Cutoff for Margins (mm) | Five-Year Outcome | Risk Factor (MVA) | |||||
|---|---|---|---|---|---|---|---|---|---|
| LC (%) | DFS (%) | DSS (%) | OS (%) | LC | DSS | OS | |||
| Kang et al. (2011–2017) Current study | 13768 | >4/0.1–4/involved | 92%/89%/87% ( | nm | 81%/76%/57% ( | 74%/67%/46% ( | Margin, depth, site (palate/buccal/retromolar/other), differentiation | Margin, ENE, depth, p-stage, sex, age, pT, pN, site (palate), differentiation | Margin, ENE, depth, second primary, sex, age, pT, pN, site (palate), differentiation |
| Lin et al. [ | 15654 | ≥5/4.0–4.9/3.0–3.9/2.0–2.9/1.0–1.9/0.1–0.9/involved | nm | nm | 81%/81%/80%/77%/72%/75%/62% ( | 76%/75%/74%/72%/66%/70%/47% ( | nm | Margin, sex, age, pT, pN, site (gum/palate), differentiation, treatment | Margin, sex, age, pT, pN, site (lip/palate), differentiation, treatment |
| Liao et al. [ | 827 | >7/≤7 | 89%/79% ( | nm | 82%/77% ( | 69%/63% ( | Margin, depth, pN, betel quit | Margin, depth, alcohol, p-stage, ENE, differentiation | Margin, depth p-stage, ENE, differentiation |
| Binahmed et al. [ | 425 | ≥2/<2/involved | 27%/24%14%/ ( | nm | nm | 68%/58%/39% ( | nm | nm | nm |
| Jang et al. [ | 325 | >5/0–5 | 97%/85% ( | nm | nm | nm | Margin, pT, pN | nm | nm |
| >5/involved | 97%/25% ( | nm | nm | nm | |||||
| Nason et al. [ | 554 | ≥5/3–4/≤2/involved | nm | 71%/70%/49%/48% ( | nm | 73%/70%/63%/39% ( | nm | nm | nm |
| Zanoni et al. [ | 381 | >5/2.3–5.0/0.01–2.2/involved | nm | nm | nm | nm | Margin, PNI, pN | nm | nm |
| Mitchell et al. [ | 591 | ≥5/ 2–5/≤2 (involved) | nm | nm | nm | 81%/75%/54% ( | nm | nm | nm |
| Loree et al. [ | 398 | ≥5/<5 | nm | nm | nm | 60%/52% ( | nm | nm | nm |
Abbreviations: MVA, multivariate analysis; LC, local control; DFS, disease-free survival; DSS, disease-specific survival; OS, overall survival; ENE, extra-nodal extension; PNI, perineural invasion; nm, not mentioned. * Chi-square test.